{"organizations": [], "uuid": "354f190da750cd76966b408b05f403c7b30abba7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180502.html", "section_title": "Archive News &amp; Video for Wednesday, 02 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-exelixis-and-invenra-enter-into-co/brief-exelixis-and-invenra-enter-into-collaboration-to-develop-novel-biologics-to-treat-cancer-idUSFWN1S917W", "country": "US", "domain_rank": 408, "title": "BRIEF-Exelixis And Invenra Enter Into Collaboration To Develop Novel Biologics To Treat Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.48, "site_type": "news", "published": "2018-05-03T04:16:00.000+03:00", "replies_count": 0, "uuid": "354f190da750cd76966b408b05f403c7b30abba7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-exelixis-and-invenra-enter-into-co/brief-exelixis-and-invenra-enter-into-collaboration-to-develop-novel-biologics-to-treat-cancer-idUSFWN1S917W", "ord_in_thread": 0, "title": "BRIEF-Exelixis And Invenra Enter Into Collaboration To Develop Novel Biologics To Treat Cancer", "locations": [], "entities": {"persons": [{"name": "deve", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "exelixis inc", "sentiment": "negative"}, {"name": "exelixis", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2 (Reuters) - Exelixis Inc:\n* EXELIXIS AND INVENRA ENTER INTO COLLABORATION TO DISCOVER AND DEVELOP NOVEL BIOLOGICS TO TREAT CANCER\n* EXELIXIS INC - COMPANIES WILL PARTNER TO ADVANCE MULTISPECIFIC ANTIBODIES IN UP TO SEVEN DISCRETE PROJECTS\n* EXELIXIS INC - EXELIXIS WILL PAY INVENRA AN UPFRONT PAYMENT OF $2.0 MILLION PLUS $2.0 MILLION AT INITIATION OF EACH DISCOVERY PROJECT Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-03T04:16:00.000+03:00", "crawled": "2018-05-03T12:26:19.052+03:00", "highlightTitle": ""}